Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial

Post time Half hour(s) ago

journal：Journal of Clinical Oncology

Authors：Thomas Pierre Walter; Julien Mazieres; Josiane Otto; Hervé Lena; Cme Lepage; Denis Smith; Jeannick Madelaine; Laurence Gérinière; Thomas Egenod; Farid El Hajbi; Aurélie Ferru; Christelle Clément-Duchene; Anne Madroszyk; Thibault Brotelle; Karine Bouhier-Leporrier; Jérme Desrame; Franois Ghiringhelli; Nicolas Paleiron; Antoine Khalil; Laurent Milot; Olivier Chevallier; Anne Couvelard; Sylvie Lantuejoul; Alexandra Langlais; Franck Morin; Michael Duruisseaux; Pierre Michel; Christophe Louvet; Virginie Westeel; Nicolas Girard;

Published date：2026-4-20

DOI：10.1200/jco-25-01657

PDF link：https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-01657

Article link：https://doi.org/10.1200/jco-25-01657

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

Post time Half hour(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial